Overview

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine
Hydrochlorothiazide
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination